Behavior of CMPCs in unidirectional constrained and stress-free 3D hydrogels

Journal of Molecular and Cellular Cardiology

Volumn 87, Issue , 2015, Pages 79-91

  van Marion, Mieke H ^a   Bax, Noortje A M ^a   van Turnhout, Mark C ^a   Mauretti, Arianna ^a   van der Schaft, Daisy W J ^a   Goumans, Marie José T H ^b   Bouten, Carlijn V C ^a  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

3D cell culture; Cardiac regeneration; Cardiomyocyte progenitor cells (CMPCs); Matrix remodeling; Mechanical forces; Tissue engineering

Indexed keywords

BIOMATERIAL; COLLAGEN TYPE 1; COLLAGEN TYPE 3; ELASTIN; FIBRONECTIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIGEL; MYOCARDIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NKX2.5; TROPONIN I; TROPONIN T; VIMENTIN; COLLAGEN; DRUG COMBINATION; LAMININ; MATRIX METALLOPROTEINASE; PROTEOGLYCAN; TIMP1 PROTEIN, HUMAN; TIMP2 PROTEIN, HUMAN;

ARTICLE; CARDIAC STEM CELL; CELL CULTURE EQUIPMENT; CELL DIFFERENTIATION; CELL ENCAPSULATION; CELL FUNCTION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CRYOPRESERVATION; CULTURE MEDIUM; CULTURE TECHNIQUE; EXTRACELLULAR MATRIX; FETUS; HUMAN; HUMAN CELL; HYDROGEL; INTERMETHOD COMPARISON; MECHANICAL STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGENERATIVE MEDICINE; SEQUENCE ALIGNMENT; STEM CELL TRANSPLANTATION; THREE DIMENSIONAL CELL CULTURE; ANIMAL; BIOSYNTHESIS; CARDIAC MUSCLE CELL; CELL CULTURE TECHNIQUE; CYTOLOGY; DRUG COMBINATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROCEDURES; STEM CELL; TRANSPLANTATION;

ANIMALS; BIOCOMPATIBLE MATERIALS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL PROLIFERATION; COLLAGEN; DRUG COMBINATIONS; FIBRONECTINS; GENE EXPRESSION REGULATION; HUMANS; LAMININ; MATRIX METALLOPROTEINASES; MYOCYTES, CARDIAC; PROTEOGLYCANS; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; STEM CELLS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84939605629     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.08.010     Document Type: Article

References (54)

1. van der Spoel T.I., Jansen of Lorkeers S.J., Agostoni P., van Belle E., Gyongyosi M., et al. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc. Res. 2011, 91(4):649-658. 10.1093/cvr/cvr113.
2. Sharif F., Bartunek J., Vanderheyden M. Adult stem cells in the treatment of acute myocardial infarction. Catheter. Cardiovasc. Interv. 2011, 77(1):72-83. 10.1002/ccd22620.
3. Novotny N.M., Ray R., Markel T.A., Crisostomo P.R., Wang M., et al. Stem cell therapy in myocardial repair and remodeling. J. Am. Coll. Surg. 2008, 207(3):429-434. 10.1016/j.jamcollsurg.2008.04.013.
4. Traverse J.H., Henry T.D., Ellis S.G., Pepine C.J., Willerson J.T., et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA 2011, 306(19):2110-2119. 10.1001/jama.2011.1670.
5. Perin E.C., Willerson J.T., Pepine C.J., Henry T.D., Ellis S.G., et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 2012, 307(16):1717-1726. 10.1001/jama.2012.418.
6. Chugh A.R., Beache G.M., Loughran J.H., Mewton N., Elmore J.B., et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation 2012, 126(11 Suppl. 1):S54-S64.
7. Bolli R., Chugh A.R., D'Amario D., Loughran J.H., Stoddard M.F., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011, 378(9806):1847-1857. 10.1016/S0140-6736(11)61590-0.
8. Segers V.F., Lee R.T. Biomaterials to enhance stem cell function in the heart. Circ. Res. 2011, 109(8):910-922. 10.1161/CIRCRESAHA.111.249052.
9. Singelyn J.M., DeQuach J.A., Seif-Naraghi S.B., Littlefield R.B., Schup-Magoffin P.J., et al. Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering. Biomaterials 2009, 30(29):5409-5416. 10.1016/j.biomaterials.2009.06.045.
10. Leor J., Amsalem Y., Cohen S. Cells, scaffolds, and molecules for myocardial tissue engineering. Pharmacol. Ther. 2005, 105(2):151-163.
11. Eschenhagen T., Zimmermann W.H. Engineering myocardial tissue. Circ. Res. 2005, 97(12):1220-1231.
12. Venugopal J.R., Prabhakaran M.P., Mukherjee S., Ravichandran R., Dan K., et al. Biomaterial strategies for alleviation of myocardial infarction. J. R. Soc. Interface 2012, 9(66):1-19. 10.1098/rsif.2011.0301.
13. Yu K., Du K.T., Fang Q., Gu Y., Mihardja S.S., et al. The use of human mesenchymal cells encapsulated in RGD modified alginate microspheres in the repair of myocardial infarction in rat. Biomaterials 2010, 31(27):7012-7020. 10.1016/j.biomaterials.2010.05.078.
14. Tous E., Purcel B., Ifkovits J.L., Burdick J.A. Injectable acellular hydrogels for cardiac repair. J. Cardiovasc. Transl. Res. 2011, 4(5):528-542. 10.1007/s12265-011-9291-1.
15. Elliott N.T., Yuan F. A review of three-dimensional in vitro tissue models for drug discovery and transport studies. J. Pharm. Sci. 2011, 100(1):59-74. 10.1002/jps.22257.
16. Dawson E., Mapili G., Erickson K., Taqvi S., Roy K. Biomaterials for stem cell differentiation. Adv. Drug Deliv. Rev. 2008, 60(2):215-228.
17. Liu H., Lin J., Roy K. Effect of 3D scaffold and dynamic culture condition on the global gene expression profile of mouse embryonic stem cells. Biomaterials 2006, 27(36):5978-5989.
18. Duan Y., Liu Z., O'Neill J., Wan L.Q., Freytes D.O., Vunjak-Novakovic G. Hybrid gel composed of native heart matrix and collagen induces cardiac differentiation of human embryonic stem cells without supplemental growth factors. J. Cardiovasc. Transl. Res. 2011, 4(5):605-615. 10.1007/s12265-011-9304-0.
19. Curtis M.W., Russell B. Micromechanical regulation in cardiac myocytes and fibroblasts: implications for tissue remodeling. Pflugers Arch. 2011, 462(1):105-117. 10.1007/s00424-011-0931-8.
20. Shav D., Einav S. The effect of mechanical loads in the differentiation of precursor cells into mature cells. Ann. N. Y. Acad. Sci. 2010, 1188:25-31. 10.1111/j.1749-6632.2009.05079.x.
21. Huang Y., Zheng L., Gong X., Jia X., Song W., et al. Effect of cyclic strain on cardiomyogenic differentiation of rat bone marrow derived mesenchymal stem cells. PLoS One 2012, 7(4). 10.1371/journal.pone.0034960.
22. Fink C., Ergun S., Kralisch D., Remmers U., Weil J., Eschenhagen T. Chronic stretch of engineered heart tissue induces hypertrophy and functional improvement. FASEB J. 2000, 14(5):669-679.
23. Hansen A., Eder A., Bonstrup M., Flato M., Mewe M., et al. Development of a drug screening platform based on engineered heart tissue. Circ. Res. 2010, 107(1):35-44. 10.1161/CIRCRESAHA.109.211458.
24. Bellas E., Chen C.S. Forms, forces, and stem cell fate. Curr. Opin. Cell Biol. 2014, 92-97. 10.1016/j.ceb.2014.09.006.
25. den Haan M.C., Grauss R.W., Smits A.M., Winter E.M., van Tuyn J., et al. Cardiomyogenic differentiation-independent improvement of cardiac function by human cardiomyocyte progenitor cell injection in ischaemic mouse hearts. J. Cell. Mol. Med. 2012, 16(7):1508-1521. 10.1111/j.1582-4934.2011.01468.x.
26. Winter E.M., van Oorschot A.A., Hogers B., van der Graaf L.M., Doevendans P.A., et al. A new direction for cardiac regeneration therapy: application of synergistically acting epicardium-derived cells and cardiomyocyte progenitor cells. Circ. Heart Fail. 2009, 2(6):643-653. 10.1161/CIRCHEARTFAILURE.108.843722.
27. Goumans M.J., de Boer T.P., Smits A.M., van Laake L.W., van Vliet P., et al. TGF-beta1 induces efficient differentiation of human cardiomyocyte progenitor cells into functional cardiomyocytes in vitro. Stem Cell Res. 2007, 1(2):138-149. 10.1016/j.scr.2008.02.003.
28. van Vliet P., Roccio M., Smits A.M., van Oorschot A.A.M., Metz C.H.G., et al. Progenitor cells isolated from the human heart: a potential cell source for regenerative therapy. Neth. Heart J. 2008, 16(5):163-169.
29. Smits A.M., van Vliet P., Metz C.H., Korfage T., Sluijter J.P., et al. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes: an in vitro model for studying human cardiac physiology and pathophysiology. Nat. Protoc. 2009, 4(2):232-243. 10.1038/nprot.2008.229.
30. Bax N.A., van Marion M.H., Shah B., Goumans M.J., Bouten C.V., van der Schaft D.W. Matrix production and remodeling capacity of cardiomyocyte progenitor cells during in vitro differentiation. J. Mol. Cell. Cardiol. 2012, 53(4):497-508. 10.1016/j.yjmcc.2012.07.003.
31. Gawlitta D., Boonen K.J., Oomens C.W., Baaijens F.P., Bouten C.V. The influence of serum-free culture conditions on skeletal muscle differentiation in a tissue-engineered model. Tissue Eng. Part A 2008, 14(1):161-171. 10.1089/ten.a.2007.0095.
32. Langelaan M.L., Boonen K.J., Rosaria-Chak K.Y., van der Schaft D.W., Post M.J., Baaijens F.P. Advanced maturation by electrical stimulation: Differences in response between C2C12 and primary muscle progenitor cells. J. Tissue Eng. Regen. Med. 2011, 5(7):529-539. 10.1002/term.345.
33. Van der Schaft D.W., van Spreeuwel A.C., Boonen K.J., Langelaan M.L., Bouten C.V., Baaijens F.P. Engineering skeletal muscle tissue from murine myoblast progenitor cells and application of electrical stimulation. J. Vis. Exp. 2013, 73. 10.3791/4267.
34. De Vries S.A., van Turnhout M.C., Oomens C.W., Erdemir A., Ito K., van Donkelaar C.C. Deformation thresholds for chondrocyte death and the protective effect of the pericellular matrix. Tissue Eng. Part A 2014, 20(13-14):1870-1876. 10.1089/ten.TEA.2013.0436.
35. De Kleijn D.P., Sluijter J.P., Smit E., Velema W., Richard A.H., et al. Furin and membrane type-1 metallproteinase mRNA levels and activation of metalloproteinase-2 are associated with arterial remodeling. FEBS Lett. 2001, 501:37-43. 10.1016/S0014-5793(01)02622-9.
36. Frangi A.F., Niessen W.J., Vincken K.L., Viergever M.A. Medical image computing and computer-assisted intervention. Multiscale Vessel Enhancement Filtering 1998, 1496:130-137. Springer Verlag, Berlin, Germany. A. Wells, A. Colchester, S.L. Delp (Eds.).
37. van der Schaft D.W., van Spreeuwel A.C., van Assen H.C., Baaijens F.P. Mechanoregulation of vascularization in aligned tissue-engineered muscle: a role for vascular endothelial growth factor. Tissue Eng. Part A 2011, 17(21-22):2857-2865. 10.1089/ten.TEA.2011.0214.
38. de Jonge N., Kanters F.M., Baaijens F.P., Bouten C.V. Strain-induced collagen organization at the micro-level in fibrin-based engineered tissue constructs. Ann. Biomed. Eng. 2013, 41(4):763-774. 10.1007/s10439-012-0704-3.
39. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25(4):402-408.
40. Rivron N.C., Vrij E.J., Rouwkema J., Le Gac S., van den Berg A., et al. Tissue deformation spatially modulates VEGF signaling and angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(18):6886-6891. 10.1073/pnas.1201626109.
41. Moore L., Fan D., Basu R., Kandalam V., Kassiri Z. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail. Rev. 2012, 17(4-5):693-706. 10.1007/s10741-011-9266-y.
42. Zimmermann W.H., Melnychenko I., Eschenhagen T. Engineered heart tissue for regeneration of diseased hearts. Biomaterials 2004, 25(9):1639-1647.
43. Dankers P.Y., Hermans T.M., Baughman T.W., Kamikawa Y., Kieltyka R.E., et al. Hierarchical formation of supramolecular transient networks in water: a modular injectable delivery system. Adv. Mater. 2012, 24(20):2703-2709. 10.1002/adma.201104072.
44. Gaetani R., Doevendans P.A., Metz C.H., Alblas J., Messina E., et al. Cardiac tissue engineering using tissue printing technology and human cardiac progenitor cells. Biomaterials 2012, 33(6):1782-1790. 10.1016/j.biomaterials.2011.11.003.
45. Grigore A., Arsene D., Filipoiu F., Cionca F., Enache S., et al. Cellular immunophenotypes in human embryonic, fetal and adult heart. Rom. J. Morphol. Embryol. 2012, 53(2):299-311.
46. Pontes Soares C., Midlej V., de Oliveira M.E., Benchimol M., Costa M.L., Mermelstein C. 2D and 3D-organized cardiac cells shows differences in cellular morphology, adhesion junctions, presence of myofibrils and protein expression. PLoS One 2012, 7(5). 10.1371/journal.pone.0038147.
47. Tiburcy M., Didie M., Boy O., Christalla P., Doker S., et al. Terminal differentiation, advanced organotypic maturation, and modeling of hypertrophic growth in engineered heart tissue. Circ. Res. 2011, 109(10):1105-1114. 10.1161/CIRCRESAHA.111.251842.
48. Li Z., Guo X., Palmer A.F., Das H., Guan J. High-efficiency matrix modulus-induced cardiac differentiation of human mesenchymal stem cells inside a thermosensitive hydrogel. Acta Biomater. 2012, 8(10):3586-3595. 10.1016/j.actbio.2012.06.024.
49. Grayson W.L., Ma T., Bunnell B. Human mesenchymal stem cells tissue development in 3D PET matrices. Biotechnol. Prog. 2004, 20(3):905-912. 10.1021/bp034296z.
50. Kurazumi H., Kubo M., Ohshima M., Yamamoto Y., Takemoto Y., et al. The effects of mechanical stress on the growth, differentiation, and paracrine factor production of cardiac stem cells. PLoS One 2011, 6(12). 10.1371/journal.pone.0028890.
51. Ulrich M.M., Janssen A.M., Daemen M.J., Rappaport L., Samuel J.L., et al. Increased expression of fibronectin isoforms after myocardial infarction in rats. J. Mol. Cell. Cardiol. 1997, 29(9):2533-2543. 10.1006/jmcc.1997.0486.
52. Wu X., Sun Z., Foskett A., Trzeciakowski J.P., Meininger G.A., Muthuchamy M. Cardiomyocyte contractile status is associated with differences in fibronectin and integrin interactions. Am. J. Physiol. Heart Circ. Physiol. 2010, 298(6):H2071-H2081. 10.1152/ajpheart.01156.2009.
53. Coker M.L., Doscher M.A., Thomas C.V., Galis Z.S., Spinale F.G. Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am. J. Physiol. 1999, 277(2 Pt 2):H777-H787.
54. Nemir S., West J.L. Synthetic materials in the study of cell response to substrate rigidity. Ann. Biomed. Eng. 2010, 38(1):2-20. 10.1007/s10439-009-9811-1.